Patents Examined by Jae W Lee
  • Patent number: 11987829
    Abstract: The present invention relates to a recombinant microorganism which is modified to be capable of producing diosmin and hesperidin and to the use thereof for producing diosmin and/or hesperidin.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: May 21, 2024
    Assignee: LES LABORATOIRES SERVIER
    Inventors: Cyrille Pauthenier, André Le Jeune, Hélène Scornec, Célia Roussel, Laetitia Joubert
  • Patent number: 11987637
    Abstract: The invention concerns methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
    Type: Grant
    Filed: January 11, 2024
    Date of Patent: May 21, 2024
    Assignee: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
  • Patent number: 11987801
    Abstract: This disclosure provides compositions and methods for altering or changing the tissue tropism, e.g., liver tropism, of adeno-associated viruses (AAV).
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: May 21, 2024
    Assignees: Massachusetts Eye and Ear Infirmary, The Schepens Eye Research Institute, Inc.
    Inventors: Luk H. Vandenberghe, Pauline Schmit, Christopher Tipper, Carmen Unzu, Eric Zinn
  • Patent number: 11987638
    Abstract: The invention concerns methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
    Type: Grant
    Filed: January 11, 2024
    Date of Patent: May 21, 2024
    Assignee: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
  • Patent number: 11987791
    Abstract: The present invention provides agents and compositions for modulating expression (e.g., enhanced or reduced expression) of a hepatocyte nuclear factor 4 alpha (HNF4?) gene by targeting an HNF4? expression control region and methods of use thereof for treating an HNF4? associated disorder, e.g., cirrhosis.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: May 21, 2024
    Assignee: Omega Therapeutics, Inc.
    Inventors: Jesse Jerome Smith, Jodi Michelle Kennedy, Jeremiah D. Farelli, Kendrick Alan Goss, Adam Walter Scheidegger, Yoseph Kassa, Christian Wessel Cobaugh, Timsi Rao
  • Patent number: 11976127
    Abstract: The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
    Type: Grant
    Filed: April 20, 2023
    Date of Patent: May 7, 2024
    Assignee: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
  • Patent number: 11970730
    Abstract: The present disclosure describes compositions of matter comprising a ribonucleoprotein complex comprising a nucleic acid-guided nuclease and a guide RNA, and further comprising and a blocking nucleic acid molecule represented by Formula III in the 5?-to-3? direction comprises: T-D-M-A-(B-L)J-C; wherein T is 17-135 nucleotides in length; D is 0-10 nucleotides in length; M is 1-25 nucleotides in length or is absent, wherein if M is absent then T-D and A-(B-L)J-C are separate nucleic acid strands; A is 0-15 nucleotides in length and comprises at least 50% sequence complementarity to D; B is 4-12 nucleotides in length and comprises at least 50% sequence complementarity to T; L is 3-25 nucleotides in length; J is an integer between 1 and 10; C is 4-15 nucleotides in length; and wherein the blocking nucleic acid molecule comprises a sequence complementary to a gRNA.
    Type: Grant
    Filed: June 10, 2023
    Date of Patent: April 30, 2024
    Assignee: VedaBio, Inc.
    Inventors: Anurup Ganguli, Ariana Mostafa, Jacob Berger, Ashish Pandey, Rashid Bashir
  • Patent number: 11965186
    Abstract: The present disclosure provides engineered nucleic acid-guided nickases and optimized scaffolds for making rational, direct edits to nucleic acids in live cells.
    Type: Grant
    Filed: February 20, 2022
    Date of Patent: April 23, 2024
    Assignee: Inscripta, Inc.
    Inventors: Juhan Kim, Benjamin Mijts
  • Patent number: 11959111
    Abstract: The present invention relates to cleaning compositions comprising polypeptides having peptidoglycan degradation activity, as well as use of the cleaning compositions for cleaning of an item such as a textile or a surface.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: April 16, 2024
    Assignee: Novozymes A/S
    Inventors: Christian Berg Oehlenschlaeger, Dorotea Raventos Segura, Jesper Salomon, Fabian Barrientos Garcia, Lillian Eva Tang Baltsen, Christian Bech Rosen
  • Patent number: 11959124
    Abstract: Disclosed are methods and systems for the analysis activity of enzyme disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) in a sample. The methods and systems disclosed herein can be useful for diagnosis of thrombotic thrombocytopenic purpura in a patient.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: April 16, 2024
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Russell Philip Grant, Christopher Michael Shuford, Meghan Norris Bradley
  • Patent number: 11959123
    Abstract: The present invention aims to provide a novel method that can quantify diaminopimelic acid-containing bacteria in a test sample. The present invention relates to a method of quantifying diaminopimelic acid-containing bacteria in a test sample, including a step of quantifying the diaminopimelic acid-containing bacteria, using, as an index, the amount of diaminopimelic acid derived from the diaminopimelic acid-containing bacteria in the test sample.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: April 16, 2024
    Assignee: SUNTORY HOLDINGS LIMITED
    Inventors: Yosuke Sato, Naoki Kasajima, Toshihiko Fukuda, Masayuki Ida
  • Patent number: 11951231
    Abstract: A therapeutic agent for intervertebral disc degeneration that contains LASCol obtained by enzymatically cleaving a terminus of collagen.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: April 9, 2024
    Assignee: KINKI UNIVERSITY
    Inventors: Takashi Yurube, Yoshiki Takeoka, Koichi Morimoto, Saori Kunii, Kaoru Omae
  • Patent number: 11952557
    Abstract: The present invention relates to alpha-amylase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: March 23, 2022
    Date of Patent: April 9, 2024
    Assignee: Novozymes A/S
    Inventors: Carsten Andersen, Chakshusmathi Ghadiyaram, Rajendra Kulothungan Sainathan, Padmavathi Balumuri, Padma Venkatachalam Iyer, Iben Damager, Astrid Munch, Sohel Dalal
  • Patent number: 11945853
    Abstract: Provided herein are polynucleic acids and expression vectors for the expression and secretion of angiotensin peptide fragments (e.g., angiotensin-(1-7)) in probiotic bacteria. Provided herein are also probiotic compositions that enable efficient, cost-effective and patient friendly oral therapeutics for treating diverse pathological conditions that involve the renin-angiotensin system (RAS), e.g., pulmonary hypertension, diabetes, diabetic complications, cardiovascular diseases, and ocular inflammatory and neurodegenerative diseases.
    Type: Grant
    Filed: June 14, 2022
    Date of Patent: April 2, 2024
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
    Inventors: Qiuhong Li, Mohan Raizada
  • Patent number: 11938157
    Abstract: Provided is Lactobacillus paracasei TCI727, deposited in the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) with a deposit number of DSM 33756. A method for improving calcium absorption of a subject in need thereof by using the Lactobacillus paracasei TCI727 or metabolites thereof is also provided. The method includes administering to the subject an effective amount of a composition comprising the Lactobacillus paracasei TCI727 or the metabolites thereof.
    Type: Grant
    Filed: July 13, 2022
    Date of Patent: March 26, 2024
    Assignee: TCI CO., LTD.
    Inventors: Yung-Hsiang Lin, Chu-Han Huang
  • Patent number: 11939605
    Abstract: Thermostable Cas9 nucleases. The present invention relates to the field of genetic engineering and more particularly to nucleic acid editing and genome modification. The present invention provides an isolated Cas protein or polypeptide fragment thereof having an amino acid sequence of SEQ ID NO: 1 or a sequence of at least 77% identity therewith. The Cas protein or polypeptide is capable of binding, cleaving, marking or modifying a double stranded target polynucleotide at a temperature in the range 20° C. and 100° C. inclusive. The invention further provides isolated nucleic acid molecules encoding the Cas9 nucleases, expression vectors and host cells. The invention also provides PAM sequences recognized by the Cas protein or polypeptide, The Cas9 nucleases disclosed herein provide novel tools for genetic engineering in general, in particular at elevated temperatures and are of particular value in the genetic manipulation of thermophilic organisms; particularly microorganisms.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: March 26, 2024
    Assignees: Wageningen Universiteit, Stichting Voor De Technische Wetenschappen
    Inventors: John Van Der Oost, Richard Van Kranenburg, Elleke Fenna Bosma, Ioannis Mougiakos, Prarthana Mohanraju
  • Patent number: 11926843
    Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: March 12, 2024
    Assignee: LifeEDIT Therapeutics, Inc.
    Inventors: Alexandra Briner Crawley, Rodolphe Barrangou, Tyson D. Bowen, Michael Coyle, Tedd D. Elich
  • Patent number: 11919919
    Abstract: This invention relates to a method for the enzymatic synthesis of oligosaccharides, preferably human milk oligosaccharides (HMOs) The method comprises the enzymatic transfer of a glycosyl moiety and subsequent removal of by-products, such as lactose, by nanofiltration using a membrane comprising an active polyamide layer.
    Type: Grant
    Filed: December 27, 2021
    Date of Patent: March 5, 2024
    Assignee: GLYCOM A/S
    Inventors: Nikolay Khanzhin, Markus Jondelius Hederos
  • Patent number: 11920130
    Abstract: The present disclosure provides gene edited modified immune cells or precursors thereof (e.g., gene edited modified T cells) comprising an exogenous T cell receptor (TCR) and/or a chimeric antigen receptor (CAR) having specificity for a target antigen, and an insertion and/or deletion in one or more endogenous gene loci, wherein the endogenous gene loci encode regulators of T cell function, thereby resulting in immune cells having enhanced function. Compositions and methods of treatment are also provided. The present invention provides methods of screening for TCR- or CAR-T cells with enhanced immune function (e.g., T cell efficacy, T cell memory, and/or T cell persistence).
    Type: Grant
    Filed: May 12, 2022
    Date of Patent: March 5, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Yangbing Zhao, Jiangtao Ren
  • Patent number: 11912745
    Abstract: Proteins, nucleic acids encoding the proteins, compositions comprising the proteins, and methods are provided. The proteins have the ability to be self-targeted to ICAM-1 and, if desired, enzymatically-released at acidic pH. The ICAM-1-targeting peptides are provided as single copies or multiples repeats, and can be separated by linkers from the enzyme segment, from which the ICAM-1 targeting peptides can be released, if desired, at acidic pH. These fusion proteins enhance the activity of the enzyme segment within or liberated from the fusion protein, and provide increased recognition and targeting of diseased organs, transport from the bloodstream across the endothelium into said diseased organ, and intracellular uptake and lysosomal trafficking by cells in them, both in peripheral tissues and the central nervous system. Representative nucleotide and amino acid sequences of these fusion proteins, as well as in vitro, cellular, and in vivo animal data are provided.
    Type: Grant
    Filed: January 7, 2022
    Date of Patent: February 27, 2024
    Assignee: University of Maryland, College Park
    Inventors: Silvia Muro, Jing Chen, Melani Solomon, Kevin Gray